Biotech Tracker
Trial resultsH2 2026a window, not a day

Phase 3 LIBREXIA-STROKE topline for milvexian (with J&J)

Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson) for Secondary stroke prevention in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsClinical trial results · also called: readout / topline data
Company
Bristol-Myers Squibb Company BMY
Drug
Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson)
For
Secondary stroke prevention
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day; the calendar never invents one
Source note
Per BioSpace's July 30, 2026 coverage of BMS Q2 earnings, LIBREXIA-STROKE findings remain expected by end of 2026. Program context: LIBREXIA-ACS was discontinued in Nov 2025 after interim futility; STROKE and AF continue.
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Bristol-Myers Squibb Company
BMY
6 upcoming · 3 past catalysts
More from BMY
Trial resultsBMYBristol-Myers Squibb CompanyH2 2026

Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Cobenfy (xanomeline-trospium) for Alzheimer's disease psychosis (ADEPT-1) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Cobenfy ADEPT-1 ADP possible interim analysis and open-label lead-in data · Clinical trial results (readout / topline data)
Drug
Cobenfy (xanomeline-trospium)
For
Alzheimer's disease psychosis (ADEPT-1)
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
Fierce Pharma July 30, 2026 on BMS Q2 call: full ADEPT program readouts pushed to begin in early 2027 and be spread across the year, but an ADEPT-1 interim and open-label lead-in data are possible later in 2026.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBMYBristol-Myers Squibb CompanyQ1 2027

Bristol-Myers Squibb Company expects to report results from its Phase 3 study of milvexian for Stroke prevention in atrial fibrillation (LIBREXIA-AF) in Q1 2027 (Jan–Mar) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
LIBREXIA-AF milvexian Ph3 AF stroke prevention readout now Q1 2027 · Clinical trial results (readout / topline data)
Drug
milvexian
For
Stroke prevention in atrial fibrillation (LIBREXIA-AF)
Stage
Phase 3 · the last stage before a drug can be approved
When
Q1 2027 · the company gave a window, not a day
Source note
existing item 'BMY|readout|2027|LIBREXIA-AF milvexian' is now more precisely guided to Q1 2027 per BMS Q2 2026 earnings commentary (Fierce Pharma, July 30, 2026); previously expected in 2026.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBMYBristol-Myers Squibb CompanyH1 2027

Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Cobenfy (xanomeline/trospium) for Psychosis associated with Alzheimer's disease (ADEPT-1/2/4) in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Cobenfy ADEPT Alzheimer's psychosis readouts begin early 2027 · Clinical trial results (readout / topline data)
Drug
Cobenfy (xanomeline/trospium)
For
Psychosis associated with Alzheimer's disease (ADEPT-1/2/4)
Stage
Phase 3 · the last stage before a drug can be approved
When
H1 2027 · the company gave a window, not a day
Source note
CEO Chris Boerner said ADEPT program topline readouts are now anticipated to begin in early 2027 and be spread across the year, with a potential ADEPT-1 interim analysis in late 2026. Timeline slipped after site 'irregularities' in ADEPT-2 and slower enrollment/event accrual.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBMYBristol-Myers Squibb Company2027

Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson) for Stroke prevention in atrial fibrillation during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
Phase 3 LIBREXIA-AF topline for milvexian delayed to 2027 · Clinical trial results (readout / topline data)
Drug
Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson)
For
Stroke prevention in atrial fibrillation
Stage
Phase 3 · the last stage before a drug can be approved
When
2027 · the company gave a window, not a day
Source note
BMS's Q2 2026 earnings presentation moved the LIBREXIA-AF topline readout to 2027 (previously guided 2026). Year-level precision only; no quarter given.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page